AUAUniversity

Microultrasound for the Detection of Prostate Cancer

Host: Mark L. Gonzalgo, MD, PhD, MBA
Guest: Christian P. Pavlovich, MD

AUA Guidelines: Non-Muscle Invasive Bladder Cancer

Host: Mark L. Gonzalgo, MD, PhD, MBA
Guests: Peter E. Clark, MD and Jeffrey M. Holzbeierlein, MD, FACS

To access the full guideline, please use the following link: https://www.auanet.org/guidelines-and-quality/guidelines/bladder-cancer-non-muscle-invasive-guideline
Please note that access to the full guideline requires user login. If you do not already have an account, you can create a free login.

Update Series (2026): Evaluating Abnormal Urine Cytology Without Clinically Demonstrable Urinary Tract Disease

Host: Mark L. Gonzalgo, MD, PhD, MBA
Guest: Sherri M. Donat, MD

Now in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology.

For more information or to subscribe to the AUA Update Series, please visit CME.auanet.org

AUA2026: Advanced Prostate Cancer in the News 2026: A Case-Based Multidisciplinary Update

CME Available: https://cme.auanet.org/URL/26DC010ONL

LEARNING OBJECTIVES:
At the conclusion of this activity, participants will be able to:
1. Initial Management of Metastatic Prostate Cancer: Evaluate and treat a patient with new diagnosed M1 prostate cancer with androgen deprivation therapy (ADT) plus be skilled to offer novel oral androgen blockers/inhibitors. Furthermore, to recognize high volume new M1 prostate cancer so as to be able to partner with GU medical oncologist for docetaxel chemotherapy in a multidisciplinary team. In addition, to recognize and employ molecular genetic testing to help dictate proper therapy.
2. Non Metastatic Castrate Resistant Prostate Cancer (M0 CRPC): Diagnose M0CRPC and to be able to educate patients about using novel oral androgen receptor targeted agents added to traditional ADT as a way to improve their patent's overall and radiographic progression-free survival. Furthermore, the skilled learner will be able to understand the differences between these three novel oral agents and to educate patients about side-effects and toxicities. Finally, to understand the pros and cons of PSMA PET scan imaging in further staging in this disease state.
3. Metastatic Castrate Resistant Prostate Cancer (M1 CRPC): Define and have a working knowledge of the latest phase III RCT results for new therapies in M1 CRPC and to be able to educate their patients on treatment options and be able to participate in a multidisciplinary team caring for men with this disease state of far advanced prostate cancer.
4. Identify that advanced prostate cancer is a complex group of disease states with an ever changing therapeutic landscape and for providers and teams to embrace the multi-disciplinary nature of care for our patients.
5. Describe the molecular and molecular genetic underpinnings of advanced prostate cancer and recognize the future will be based on a more personalized therapy landscape including PARP inhibition, Immune Checkpoint agents and novel AR targeted agents emerging in 2026 and beyond.

ACKNOWLEDGEMENTS:
Support provided by independent educational grants from:

Astellas
Lantheus Medical Imaging
Novartis Pharmaceuticals Corporation
Pfizer, Inc

AUA2026: Should I Order a PET Scan? Integrating Molecular Imaging into Urologic Oncology Clinical Practice: Current Approaches and Future Opportunities

CME Available: https://cme.auanet.org/URL/26DC041ONL

LEARNING OBJECTIVES:
At the conclusion of this activity, participants will be able to:
1. Analyze the best available evidence on the current diagnostic imaging options for prostate, kidney, bladder, and testis cancer detection, staging, and follow-up.
2. Describe the benefits of combined functional and anatomic information gained through accurate matching of anatomic (CT/MRI) and functional (PET) images.
3. Debate the strengths and limitations of emerging molecular imaging techniques compared to existing diagnostic tests.
4. Optimally stage urologic oncology patients by understanding the performance characteristics of standard and emerging molecular imaging modalities.
5. Define the emerging role of PET imaging and novel radiotracers to assess chemotherapy and immunotherapy response.
6. Formulate a strategic plan for appropriate integration of molecular imaging into clinical practice.

ACKNOWLEDGEMENTS:
Support provided by independent educational grants from:

Astellas
Lantheus Medical Imaging
Novartis Pharmaceuticals Corporation
Pfizer, Inc